KCNMB1 antibody
- Known as:
- KCNMB1 (anti-)
- Catalog number:
- orb101774
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- KCNMB1 antibody
Related genes to: KCNMB1 antibody
- Gene:
- KCNMB1 NIH gene
- Name:
- potassium calcium-activated channel subfamily M regulatory beta subunit 1
- Previous symbol:
- -
- Synonyms:
- hslo-beta
- Chromosome:
- 5q35.1
- Locus Type:
- gene with protein product
- Date approved:
- 1997-12-05
- Date modifiied:
- 2016-10-11
Related products to: KCNMB1 antibody
Related articles to: KCNMB1 antibody
- Septic shock is characterized by severe circulatory failure, microvascular dysfunction, and metabolic derangement. Methylene blue (MB) and vitamin B12 (VB12) have each shown potential benefit in vasodilatory shock, but the biological effects of their combined use remain unclear. - Source: PubMed
Publication date: 2026/08/06
Shan KejiZhao JinlingTang KunLei YuyingMao Fukang - Acute myeloid leukemia (AML) remains challenging to treat due to clinical heterogeneity and a lack of prognostic biomarkers. To address this, we developed a prognostic signature based on platelet-related genes (PRGs). By analyzing transcriptomic data from TCGA-LAML, GSE146173, and Beat AML 2.0 cohorts, we identified and validated an 11-gene signature (PSME2, PPIF, SYTL4, S100A4, CCND3, SMIM15, PARVB, STXBP5, KCNMB1, GABRE, SLC50A1) using LASSO-Cox regression. This model effectively stratified patients into high- and low-risk groups with distinct survival outcomes (p < 0.001) and demonstrated high predictive accuracy (1-/3-/5-year AUC: 0.832/0.782/0.880). High-risk patients exhibited immunosuppressive features, including upregulated immune checkpoints (CD274, CTLA4, HAVCR2, LAG3, PDCD1LG2, PDCD1), prominent monocyte infiltration, and reduced dendritic`11 cell activity. Drug sensitivity analysis suggested gefitinib, zebularine, and simvastatin as potential therapies for high-risk AML (p < 0.05). We further validated the signature's prognostic value using qPCR and clinical grouping. Notably, in vitro studies indicated that KCNMB1 facilitates AML progression. In conclusion, our robust PRG-based model elucidates the link between platelet biology, immune dysregulation, and therapeutic vulnerability in AML, offering clinical utility for risk stratification and treatment decisions. - Source: PubMed
Wu YiChen WanjiaGong SiqiWang JiajiaZhai Zhimin - Adequate renal perfusion is critical for maintaining kidney function, and its impairment contributes significantly to acute kidney injury (AKI) and related cardiovascular complications. Dopamine (DA) is clinically employed to improve renal perfusion, but its efficacy remains controversial due to paradoxical vasoconstriction at higher doses. - Source: PubMed
Publication date: 2026/06/22
Kang XuyaJin HanZheng YaoyaoZhang KejiaZhu GuangxuanWang XinyingXu ChaojieZhang ChiHe LeiYu ZhuoyangXue GenlongLiu LijunZhang YanYao LinDong ErdanLiu Yahan - Cellular stiffness impacts multiple steps of cancer metastasis, but mechanisms that regulate the stiffness of cancer cells remain poorly understood. Here, we identified potassium efflux and potassium calcium-activated channel subfamily M regulatory beta subunit 1 (KCNMB1), an auxiliary subunit of the large conductance calcium-activated potassium (BK) channels, as regulators of cellular stiffness downstream of myocardin-related transcription factor A (MRTFA). In primary pericytes, KCNMB1 knockdown increased cellular stiffness, which is consistent with the role of potassium efflux in promoting relaxation during excitation-contraction coupling. In a striking contrast, however, KCNMB1 knockdown decreased cancer cells' stiffness. Softer cancer cells were resistant to natural killer (NK) cell mediated cytotoxicity and the low KCNMB1 expression was associated with reduced survival in breast cancer patients. Importantly, pharmacological activation of BK channels reduced metastatic burden in mice and improved lysis of cancer cells by cytotoxic T lymphocytes. These results highlight the ionic regulation of stiffness in cancer cells and point to BK channel agonism as a therapeutic approach. - Source: PubMed
Publication date: 2026/06/02
Gajda Alexa MHaloul MohamedPai VinayMollaeian KeyvanPatel Khushi JRodríguez-López RaymundoBeverley Katie MSanborn Mark ALee KihakCastillo Caitlyn CWilk Stephanie MWolska Beata MHossen FarukMendenhall Eron NLee James CLevitan IrenaRehman JaleesEr Ekrem Emrah - In this study, we evaluated the beneficial vascular effects of a newly semi-synthesized chalcone derived from the Senecio nutans metabolite-1 [4-hydroxy-3-(3-methyl-2-butenyl) acetophenone] in hypertensive rats. We investigated chalcone (CHAL13) through functional assays in spontaneously hypertensive rat (SHR) aorta. We also used fluorescence microscopy, RT-qPCR, molecular docking and X-ray crystallography. - Source: PubMed
Publication date: 2026/05/14
Asunción-Alvarez DanielPalacios JavierCifuentes FrediRuiz Karina BParedes AdriánBrito IvánDelgado Gerzon ENwokocha Chukwuemeka RParra Claudio